Special Issue

Immune Checkpoint Inhibitors in Cutaneous Oncology

Message from the Guest Editor

Checkpoint inhibitors are widely used in cutaneous malignancies. These cancers include, but are not limited to, melanoma of cutaneous origin, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. In the last 10 years, the prognosis of these cancers has improved due to the introduction of checkpoint blockades into the clinic. The current FDA-approved agents are monoclonal antibodies that are directed against the checkpoint molecules on the surface of immune or cancer cells (e.g., PD-1, PD-L1, CTLA-4, and LAG-3).

The goal of this Special Issue is to develop a clinical summary of the current state-of-the-art treatments for cutaneous malignancies that involve checkpoint blockades, discuss immune-mediated reactions to checkpoint inhibition, and begin to understand the key mechanisms of current checkpoint blockade inhibition identified in laboratory studies to mitigate resistance. Clinical or translational informatics papers that describe how these agents can be delivered efficiently in the clinic or which describe new pipelines that elucidate new therapeutic approaches for enhancing checkpoint blockade efficacy in cutaneous malignancies are also welcome.

Guest Editor

Dr. Joseph Markowitz

Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA

Deadline for manuscript submissions

closed (15 October 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/117692

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)